NY-ESO-1-specific redirected T cells with endogenous TCR knockdown mediate tumor response and cytokine release syndrome.
J Immunother Cancer. 2022 Jun;10(6):e003811. doi: 10.1136/jitc-2021-003811.
J Immunother Cancer. 2022.
PMID: 35768164
Free PMC article.
Clinical Trial.